Solid-state workflows such as salt screening, crystal-form screening, and co-crystal screening are often applied at early stages of a project life cycle when material supply is limited and time-pressures are great Therefore, it is essential that the analytical components of these workflows are fast, material efficient and afford the highest decision making power possible. Elements of the Optiform™ Technologies platform that deliver fast and effective solid-state decisions will be presented in detail at the technology showcase. Catalent stands behind our industry expertise, platform, technologies, and screening workflows to provide customers with the Optiform™ Technology guarantee, and has the scientific, regulatory, and product development expertise to support a vast range of projects – from oral to inhalation to sterile.
As the current Director of Optiform™ Technologies at Catalent Pharma Solutions, Dr. David Igo combines novel automation tools and solid-state workflows to support the discovery and evaluation of crystalline forms, salts, and co-crystals. He began his industrial career with Glaxo Inc. (now GlaxoSmithKline, “GSK”) in 1991, supporting various aspects of drug development including pre-formulation, product development, chemical development, materials characterization and technology development. While working at GSK, Dr. Igo co-invented a variety of high-throughput technologies utilized in solid-state screening along with a range of unique crystalline salts and solid-state forms of GSK compounds. Dr. Pingyun Chen serves as the Manager of Optiform™ Technologies at Catalent Pharma Solutions. He began his pharmaceutical career in 1999 working at GlaxoWellcome. After spending one year as a principal research scientist in the crystallization process laboratory at Eli Lilly, he returned to chemical development at Glaxo Inc. to provide global salt and polymorph screening and selection support of drug candidates from discovery through commercialization. Dr. Chen has given multiple presentations at national meetings, co-authored a book chapter on the application of vibrational spectroscopy in pharmaceutical development, and is named as a co-inventor on multiple patents.
To arrange a follow-up interview with Dr. Pingyun Chen and Dr. David Igo, please contact Patricia McGee at media@catalent.com
To learn more about the Optiform™ compound screening technology, visit:
http://www.catalent.com/index.php#development/solid-state-services/overview
For more information or to register for the conference, visit: http://www.informex.com/register1
To contact the Optiform™ Technologies team of experts with specific solid-state screening inquiries or to arrange a consultation with the Catalent team at the upcoming Informex conference, please contact David.Igo@catalent.com
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 28 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
